Karakus, AbdullahHatipoglu, UgurKatircilar, YavuzErkurt, Mehmet AliYilmaz, SedaCagliyan, Gulsum AkgunOzturk, Fahir2026-04-042026-04-0420251473-05021878-1683https://doi.org/10.1016/j.transci.2025.104183https://hdl.handle.net/11616/109402Background: We conducted a multi-center retrospective non-randomized study to clarify roles of 2 and 3 gr/m2 doses of Cyclophosphamide (Cy) for stem cell mobilization in Multiple Myeloma. Material and methods: This study analyzed 169 adult patients who received Cy-based mobilization regimen at doses 2 and 3 gr/m2 between 2018 and 2024. All patients included in this study were 18 years old and older. Patients divided into two groups; group 1 represents 2 gr/m2 treated patients, and group 2 represents 3 gr/m2 dosing. These two groups then compared in terms of CD34+ cell number collected by apheresis, apheresis days, peak peripheral blood CD34+ value and rates of mobilization failures. Results: Higher doses of Cy yielded more hematopoietic stem cells compared to the lower dose Cy [10.00 (3.00-28.90) vs 9.01 (5.00-14.90), p = 0.002]; while mobilization failures and apheresis days were comparable across groups (p = 0.112 and p = 0.648, respectively). Apheresis days required for adequate stem cell harvest among groups was found statistically similar (p = 0.648). Conclusion: This study indicated the superior efficacy of 3 gr/m2 dose of Cy in terms of stem cell yield. However, mobilization failure and prolonged apheresis sessions were not issues with lower doses.eninfo:eu-repo/semantics/closedAccessApheresisCyclophosphamideHematopoietic Stem Cell MobilizationMultiple MyelomaArticle6444062797810.1016/j.transci.2025.1041832-s2.0-105009694556Q3WOS:001529471600002Q40000-0003-1277-51050000-0003-3836-39850000-0002-3285-417X0000-0003-1381-4188